Enzistal - P tablets p / o, No. 20

• Substitution therapy for exocrine pancreatic insufficiency: chronic pancreatitis; pancreatectomy after irradiation

• Dyspepsia cystic fibrosis flatulence diarrhea of ??non-infectious genesis.

• Impaired assimilation of food (condition after resection of the stomach and small intestine);

• To improve the digestion of food in persons with normal gastrointestinal tract function in case of errors in nutrition (consumption of fatty foods, large amounts of food, irregular nutrition) and in case of impaired chewing function, a sedentary lifestyle, prolonged immobilization.

• Remheld's syndrome (gastrocardiac syndrome).

• Preparation and X-ray examination and ultrasound of the abdominal organs.

EnzistalЃ-P is taken orally without chewing during or immediately after a meal with plenty of liquid.

The average dose for adults is 1-2 tablets at the beginning of a meal.

Depending on the degree of pancreatic insufficiency and the quality and quantity of food consumed, the dose can be increased to 2-4 tablets at the beginning of the meal. Higher doses are prescribed by your doctor. The maximum daily dose is 15-20 thousand units / kg (in terms of lipase). For children, the dose is selected by the doctor. Usually, 1 tablet is prescribed 3 times a day during meals.

The duration of treatment can vary from several days (in case of digestive disorders, errors in the diet) to several months or even years (if constant substitution therapy is necessary).

Each tablet contains:

Active substance:

Pancreatin - 116.17 mg (with minimal enzymatic activity

amylase 4200 U Ph.Eur., Lipase 3500 U Ph.Eur, protease 250 U Ph.Eur);

Excipients: lactose monohydrate - 44.83 mg, microcrystalline cellulose - 168.00 mg, magnesium stearate - 4.00 mg, colloidal silicon dioxide - 2.00 mg, sodium carboxymegyl starch - 15.00 mg.

Sheath: hypromellose - 6.10 mg, macrogol 60,000 - 61 mg, titanium dioxide - 2.91 mg, cellulose acetate phthalate - 25.00 mg, diethyl phthalate - 4.50 mg, azorubin (carmoisin) - 0.78 mg, white beeswax - 0.10 mg.

• Hypersensitivity to the components of the drug,

• acute pancreatitis,

• exacerbation of chronic pancreatitis,

• children up to age 3 years.

Trade name of the drug

EnzistalЃ-P

International non-proprietary name

Pancreatin

Dosage form

enteric-coated tablets

Composition

Each tablet contains:

Active substance:

Pancreatin - 116.17 mg (with minimal enzymatic activity

amylase 4200 U Ph.Eur., Lipase 3500 U Ph.Eur, protease 250 U Ph.Eur);

Excipients: lactose monohydrate - 44.83 mg, microcrystalline cellulose - 168.00 mg, magnesium stearate - 4.00 mg, colloidal silicon dioxide - 2.00 mg, sodium carboxymegyl starch - 15.00 mg.

Sheath: hypromellose - 6.10 mg, macrogol 60,000 - 61 mg, titanium dioxide - 2.91 mg, cellulose acetate phthalate - 25.00 mg, diethyl phthalate - 4.50 mg, azorubin (carmoisin) - 0.78 mg, white beeswax - 0.10 mg.

Description

Pink, round, biconvex enteric-coated tablets.

Pharmacotherapeutic group

digestive enzyme

ATX code

A09AA

Pharmacodynamics:

The digestive enzyme remedy compensates for the deficiency of pancreatic enzymes and has protealytic amylolytic and lipolytic effects. The pancreatic enzymes included in the composition (alpha-amylase lipase trypsin chymotrypsin) promote the breakdown of proteins to amino acids fats - to glycerol and fatty acids of starch - to dextrins and monosaccharides improves the functional state of the gastrointestinal tract promotes rapid and complete digestion of food relieves symptoms arising from indigestion (relieves the sensation heaviness and overflow in the stomach; flatulence diarrhea) normalizes digestion. Trypsin suppresses the stimulated secretion of the pancreas, providing an analgesic effect. Pancreatic enzymes are released from the dosage form in the alkaline environment of the small intestine.protected from the action of gastric juice by the membrane.

Indications:

• Substitution therapy for exocrine pancreatic insufficiency: chronic pancreatitis; pancreatectomy after irradiation

• Dyspepsia cystic fibrosis flatulence diarrhea of ??non-infectious genesis.

• Impaired assimilation of food (condition after resection of the stomach and small intestine);

• To improve the digestion of food in persons with normal gastrointestinal tract function in case of errors in nutrition (consumption of fatty foods, large amounts of food, irregular nutrition) and in case of impaired chewing function, a sedentary lifestyle, prolonged immobilization.

• Remheld's syndrome (gastrocardiac syndrome).

• Preparation and X-ray examination and ultrasound of the abdominal organs.

Contraindications:

• Hypersensitivity to the components of the drug,

• acute pancreatitis,

• exacerbation of chronic pancreatitis,

• children up to age 3 years.

Pregnancy and lactation:

During pregnancy and lactation, the drug is prescribed only if the expected benefit to the mother outweighs the potential risk to the fetus or child.

Method of administration and dosage:

EnzistalЃ-P is taken orally without chewing during or immediately after a meal with plenty of liquid.

The average dose for adults is 1-2 tablets at the beginning of a meal.

Depending on the degree of pancreatic insufficiency and the quality and quantity of food consumed, the dose can be increased to 2-4 tablets at the beginning of the meal. Higher doses are prescribed by your doctor. The maximum daily dose is 15-20 thousand units / kg (in terms of lipase). For children, the dose is selected by the doctor. Usually, 1 tablet is prescribed 3 times a day during meals.

The duration of treatment can vary from several days (in case of digestive disorders, errors in the diet) to several months or even years (if constant substitution therapy is necessary).

Side effects:

Allergic reactions are rare - diarrhea or constipation, nausea, discomfort in the epigastric region. With long-term use in high doses - hyperuricosuria when using high doses in patients with cystic fibrosis - strictures in the ileocecal section and in the ascending colon.

Overdose:

Symptoms: hyperuricosuria, hyperuricemia. Children have constipation. Treatment: drug withdrawal symptomatic therapy.

Interaction:

With simultaneous use with EnzistalЃ-P, it is possible to reduce the absorption of iron preparations.

Release form / dosage:

Enteric-coated tablets.

Packaging:

10 tablets in Al / Al. blister. 1 2 4 or 8 blisters of 10 tablets with instructions for use are packed in a cardboard box.

Storage conditions:

Store at a temperature not exceeding 25 ? C.

Keep out of the reach of children.

Shelf life:

3 years. Do not use after the expiration date indicated on the package.

Vacation conditions

Without recipe